175 related articles for article (PubMed ID: 37579206)
1. Immunological Monitoring in Hepatitis C Virus Controlled Human Infection Model.
Shoukry NH; Cox AL; Walker CM
Clin Infect Dis; 2023 Aug; 77(Suppl 3):S270-S275. PubMed ID: 37579206
[TBL] [Abstract][Full Text] [Related]
2. Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response.
Vijayamahantesh V; Patra T; Meyer K; Alameh MG; Reagan EK; Weissman D; Ray R
J Virol; 2022 Jun; 96(12):e0052322. PubMed ID: 35612312
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up.
Hartlage AS; Kapoor A
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452460
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity against hepatitis C virus infection.
Elliot LN; Lloyd AR; Ziegler JB; Ffrench RA
Immunol Cell Biol; 2006 Jun; 84(3):239-49. PubMed ID: 16509830
[TBL] [Abstract][Full Text] [Related]
5. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.
Hartlage AS; Walker CM; Kapoor A
J Virol; 2020 May; 94(10):. PubMed ID: 32102885
[TBL] [Abstract][Full Text] [Related]
6. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.
Alvarez-Lajonchere L; Dueñas-Carrera S
Int Rev Immunol; 2012 Jun; 31(3):223-42. PubMed ID: 22587022
[TBL] [Abstract][Full Text] [Related]
7. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
8. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.
Gummow J; Li Y; Yu W; Garrod T; Wijesundara D; Brennan AJ; Mullick R; Voskoboinik I; Grubor-Bauk B; Gowans EJ
J Virol; 2015 Aug; 89(15):7991-8002. PubMed ID: 26018154
[TBL] [Abstract][Full Text] [Related]
9. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial.
Phelps CC; Walker CM; Honegger JR
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372558
[TBL] [Abstract][Full Text] [Related]
10. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
[TBL] [Abstract][Full Text] [Related]
11. Success and failure of virus-specific T cell responses in hepatitis C virus infection.
Neumann-Haefelin C; Thimme R
Dig Dis; 2011; 29(4):416-22. PubMed ID: 21894013
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection.
Lee H; Jeong M; Oh J; Cho Y; Shen X; Stone J; Yan J; Rothkopf Z; Khan AS; Cho BM; Park YK; Weiner DB; Son WC; Maslow JN
Sci Rep; 2017 Mar; 7():43531. PubMed ID: 28266565
[TBL] [Abstract][Full Text] [Related]
13. Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus.
Mekonnen ZA; Grubor-Bauk B; English K; Leung P; Masavuli MG; Shrestha AC; Bertolino P; Bowen DG; Lloyd AR; Gowans EJ; Wijesundara DK
J Virol; 2019 Oct; 93(19):. PubMed ID: 31292249
[TBL] [Abstract][Full Text] [Related]
14. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
15. Immune responses in hepatitis C: is virus or host the problem?
Darling JM; Wright TL
Curr Opin Infect Dis; 2004 Jun; 17(3):193-8. PubMed ID: 15166820
[TBL] [Abstract][Full Text] [Related]
16. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.
Puig M; Mihalik K; Tilton JC; Williams O; Merchlinsky M; Connors M; Feinstone SM; Major ME
Hepatology; 2006 Sep; 44(3):736-45. PubMed ID: 16941702
[TBL] [Abstract][Full Text] [Related]
17. Protective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System.
Martínez-Donato G; Piniella B; Aguilar D; Olivera S; Pérez A; Castañedo Y; Alvarez-Lajonchere L; Dueñas-Carrera S; Lee JW; Burr N; Gonzalez-Miro M; Rehm BH
Clin Vaccine Immunol; 2016 Apr; 23(4):370-8. PubMed ID: 26888185
[TBL] [Abstract][Full Text] [Related]
18. Broadening CD4
Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
[TBL] [Abstract][Full Text] [Related]
19. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
Han JW; Sung PS; Hong SH; Lee H; Koh JY; Lee H; White S; Maslow JN; Weiner DB; Park SH; Jeong M; Heo J; Ahn SH; Shin EC
J Hepatol; 2020 Jul; 73(1):72-83. PubMed ID: 32088322
[TBL] [Abstract][Full Text] [Related]
20. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
Front Immunol; 2019; 10():1145. PubMed ID: 31178869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
